Aurinia Pharmaceuticals Announces Strong Financial Performance for Q4 and Full Year 2024, Provides Corporate Updates Fourth Quarter and Full-Year 2024 Financial Performance Highlights Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a leading…
Genethon Advances Gene Therapy Innovations on Rare Disease Day 2025 Genethon, a pioneering gene therapy research organization founded by the AFM-Telethon, marks Rare Disease Day by showcasing groundbreaking technological advancements…
Avitia Unveils AI-Powered Platform for Fast, Point-of-Care Cancer Testing Avitia, an AI company providing end-to-end testing solutions to rapidly identify cancer mutations and applicable treatments, has officially launched its business…
LEO Pharma’s Anzupgo® Meets Phase 3 Endpoint in China for Chronic Hand Eczema LEO Pharma A/S, a global leader in medical dermatology, has announced positive results from the double-blind treatment…
Healx Begins Phase 2 Trial Dosing for HLX-1502 in Neurofibromatosis Type 1 Healx, an AI-driven, clinical-stage biotechnology company focused on developing treatments for rare diseases, has announced a major milestone…
Glaukos Receives FDA Acceptance for Epioxa™ NDA Submission Glaukos Corporation (NYSE: GKOS), a leading ophthalmic pharmaceutical and medical technology company specializing in innovative therapies for the treatment of glaucoma, corneal…
Bruker Expands Proteomics Capabilities with New Software at US HUPO At the 21st Annual US HUPO Conference, Bruker Corporation (Nasdaq: BRKR) announced significant advancements in 4D-Proteomics™ performance, software, and applications…
Halda Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of HLD-0915 for Metastatic Castration-Resistant Prostate Cancer Halda Therapeutics, a clinical-stage biotechnology company focused on developing a novel class of…
Synnovation Therapeutics Doses First Patient in Phase I Trial for PI3Kα Inhibitor SNV4818 Synnovation Therapeutics Initiates Phase I Trial for SNV4818: A Potential Best-in-Class Pan-Mutant-Selective PI3Kα Inhibitor Introduction Synnovation Therapeutics,…
AN2 Therapeutics Announces Strategic Update on Phase 3 EBO-301 Trial for Treatment-Refractory MAC Lung Disease AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company dedicated to discovering and developing innovative small-molecule…
Latus Bio Presents Preclinical Data Supporting Its Huntington’s Disease Gene Therapy Program Latus Bio, Inc. (Latus), a biotechnology company pioneering advancements in adeno-associated virus (AAV) gene therapy, is pleased to…
FDA Accepts sBLA for Opdivo® + Yervoy® in MSI-High/dMMR Cancers U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with…